New article in NY Times addressing the new federal

New article in NY Times addressing the new federal effort to assist in the development of therapeutics, unfortunately just pairing interferon beta with Remdesivir. At lease its not just a singular focus on vaccines.

Quote:

---

Federal Study of Covid Treatments Enters a New Phase

I commented on the article:

Quote:

---

I am disappointed and dismayed that the most promising therapeutic, Leronlimab, is not part of any federally supported trials. Leronlimab is an immune modulator, a monoclonal antibody which blocks CCR5 receptors on a range of immune cells, such as macrophages, eosinophils and t-lymphocytes. Blocking CCR5 prevents the movement of these cells to areas of inflammation, stopping the runway inflammatory cascade of the cytokine storm.

Leronlimab reduced disease progression in moderate covid patients, with 50% of Leronlimab treated patients showing improvement, versus 20% in placebo, p=0.02

Leronlimab is awaiting Emergency Use Authorization by the FDA and Fast Track designation by the UK regulatory authorities. With approval, this can bridge the gap until effective vaccines are developed, manufactured and distributed widely

I hope that my comments are posted.

---

---